Clinical Trial: ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

U.S., Jan. 31 -- ClinicalTrials.gov registry received information related to the study (NCT06800963) titled 'ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG' on Jan. 24.

Brief Summary: This is a phase 1/2, open-label, multicenter study of intravesical rMBCG in participants with NMIBC who have not received BCG and have histologically confirmed presence of CIS or have primary or recurrent stage Ta and/or T1 papillary tumors following TUR.

Study Start Date: Feb., 2025

Study Type: INTERVENTIONAL

Condition: NMIBC

Intervention: BIOLOGICAL: Intravesical Recombinant Mycobacterium (rMBCG)

19.2e8 CFU (1 vial) rMBCG via a urinary catheter in the bladder (ie, in...